Latest papers

Proceedings of the XIIth International Symposium on Advances in Targeted Therapies. April 14-18, 2010.

Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications.

Functional capacity in rheumatoid arthritis patients: comparison between Spanish and Brazilian sample.

Adenosine deaminase and C-reactive protein in diagnosing and monitoring of rheumatoid arthritis.

Low prevalence of reactive PPD prior to infliximab use: comparative study on a population sample of Hospital Geral de Fortaleza.

[Rheumatology. TNF alpha-inhibitors: infection risks? Practical recommendations].

Clinical guidelines: Classifying RA the 2010 way--what does it mean for the clinic?

Methotrexate ameliorates pristane-induced arthritis by decreasing IFN-γ and IL-17A expressions.

[The pharmacotherapy of spondyloarthritis].

Interleukin 6 inhibition - RA and beyond.

TNF inhibitors for rheumatoid arthritis - a year in review.

Clinical significance of autoantibodies induced by infliximab treatment: two-year follow-up after infliximab discontinuation.

A critical look at diagnostic criteria: time for a change?

Rheumatoid arthritis of the cervical spine--clinical considerations.

Juvenile idiopathic arthritis - an update on pharmacotherapy.

Differences in treat-to-target in patients with rheumatoid arthritis versus hypertension and diabetes--consequences for clinical care.

Psoriatic arthritis - treatment update.

Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review.

Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932).

PTPN22 1858C>T polymorphism is strongly associated with rheumatoid arthritis but not with a response to methotrexate therapy.